Skip to main content
. 2018 Dec 17;10(4):284. doi: 10.3390/pharmaceutics10040284

Figure 2.

Figure 2

Representative T2 weighted images of subcutaneous CT26 tumors (red arrows) before (A) and 1 h (B), 4 h (C) and 24 h (D) after i.v. injection of MNP-HSA@PS.